Previous close | 137.54 |
Open | 140.18 |
Bid | 143.06 x 100 |
Ask | 143.24 x 300 |
Day's range | 136.01 - 145.22 |
52-week range | 89.04 - 148.37 |
Volume | |
Avg. volume | 888,567 |
Market cap | 14.386B |
Beta (5Y monthly) | 0.28 |
PE ratio (TTM) | 57.91 |
EPS (TTM) | 2.47 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 29 Dec 1995 |
1y target est | 153.29 |
Neurocrine stock rose Wednesday after the leading biotech topped Wall Street's sales expectations and wrapped a key regulatory filing.
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neurocrine (NBIX) delivered earnings and revenue surprises of -59.62% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?